8 Dec 2021 09:15
MGC Pharmaceuticals Ltd.
Issue of Shares
8 December 2021
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') advises that it has released the following announcements on the ASX's Market Announcement Platform today in relation the issue of securities in MGC Pharma.
1. Appendix 2A - Application for quotation of securities - Capital Raising
MGC Pharma has requested quotation on the ASX of 275,000,000 MGC Pharma shares issued to investors under the UK Placing announced on 30 November 2021.
A copy of the Announcement can be found at the following URL:
https://www.asx.com.au/asxpdf/20211208/pdf/453yd9g6rhhr80.pdf
2. Appendix 2A - Application for quotation of securities - Extension of Convertible Notes maturity date
750,000 MGC Pharma shares were issued under a previously announced agreement to extend the maturity date of A$2,100,000 final tranche Convertible Notes (Notes) held by Mercer Global Opportunity Fund LLC (Mercer), by 12 months, to 24 November 2022.
A copy of the Announcement can be found at the following URL:
https://www.asx.com.au/asxpdf/20211208/pdf/453ydfchtt2z37.pdf
-Ends-
Authorised for release by the Chairman, for further information please contact:
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.com.au | MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 info@mgcpharma.com.au |
UK Broker - Turner Pope Andy Thacker +44 203 657 0050 info@turnerpope.com | UK PR Advisors - Tavistock Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk
|
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma